Devin Murray is the SVP, Partnerships & Alliances at Kyverna Therapeutics. Devin brings 25 years of experience across business development, alliance management, commercial strategy, and drug manufacturing operations. Most recently he served as Chief Operating Officer at Cellevolve Bio. There he led early commercial strategy, corporate development, and the implementation of the validated cell therapy platform that supported the phase 2 IND clearance for CEVST-01-JC, an allogeneic cell therapy for the treatment of progressive multifocal leukoencephalopathy (PML). Prior to Cellevolve Bio, Devin was VP Cell Therapy Platform at Atara Bio, where he led the global go-to-market strategy and platform implementation for EBVALLO™ (tabelecleucel), the first ever approved allogeneic T-cell immunotherapy.

Before Devin entered the cell therapy space with Atara, he was at Exelixis where he was instrumental in establishing global development and commercialization partnerships with Takeda and Ipsen, and facilitating alignment with a number of other collaborations with both large and early stage companies. At Exelixis Devin also had leadership roles in the commercial launches of CABOMETYX® and COMETRIQ®. Prior to Exelixis, Devin was at Amgen for eight years in roles of increasing responsibility, across Market Access, Marketing, and Sales. Devin began his career with Johnson & Johnson, spending five years running GMP manufacturing operations as a process engineer.

Devin earned an M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. in Chemical Engineering from Drexel University in Philadelphia.